

MERCK RESEARCH LABORATORIES
Division of Merck & Co., Inc.
West Point, Pennsylvania 19486

28-JAN-2009

Re: MK-0683/blinded therapy

Dear Doctor:

This letter is to provide follow-up information on an adverse experience concerning MK-0683/blinded therapy which has been reported to you previously.

U.S. Food and Drug Regulations require sponsors of clinical studies conducted under an IND to notify the FDA of any serious and unexpected adverse experiences occurring in a clinical study filed under that IND when either the investigator or the sponsor believes that there is a reasonable possibility that the experience may have been drug related or if the drug relationship is unknown. The sponsor is also required to inform all investigators working with the particular drug under the IND.

In compliance with these requirements, the enclosed report has been submitted to the FDA and, because you are an investigator in a clinical study under this IND, a copy is enclosed for your information.

Please append this report to the Confidential Investigator's Brochure for the appropriate investigational product or to the Product Circular for the appropriate marketed product and retain in your files.

Please submit a copy of this report promptly (within less than 30 days of receipt) to your Institutional Review Board(s) even though the report may not involve a patient in your study.

This report does not necessarily reflect a conclusion by Merck or the FDA that the drug caused or contributed to the adverse experience. If you have any questions about this report, please contact the Merck monitor for your study.

Enclosure(s): WAES # 0711USA07005, GENSTUDY # 056-0042, AN # 64503

MedWatch

MERCK Human Health Division

For use by user-facilities,
distributors and manufacturers for
MANDATORY reporting

Merck Facsimile of FDA Form 3500A
Approved by FDA (10/21/1993)

The FDA Medical Products Reporting Program

Page 1

Mfr report #	WAES 0711USA07005
UF/Dist report #	
	FDA Use Onl

A. Patient information			
1. Patient identifier Confidential AN 64503 in confidence	2. Age at time of event: or <u>61</u> years Date of Birth: <u>10/03/1946</u>	3. Sex <input type="checkbox"/> Female <input checked="" type="checkbox"/> Male	4. Weight <u>180</u> lbs

B. Adverse event or product problem	
1. <input checked="" type="checkbox"/> Adverse event and / or	<input type="checkbox"/> Product problem (e.g., defects/malfunctions)
2. Outcomes attributed to adverse event (check all that apply)	
<input checked="" type="checkbox"/> Death <u>11/24/2007</u> (mm/dd/yyyy)	<input type="checkbox"/> Disability or Permanent Damage
<input checked="" type="checkbox"/> Life-threatening	<input type="checkbox"/> Congenital Anomaly/Birth Defect
<input checked="" type="checkbox"/> Hospitalization-initial or prolonged	<input type="checkbox"/> Other Serious(Important Medical Events)
<input type="checkbox"/> Required Intervention to Prevent Permanent Impairment/Damage (Devices)	
3. Date of event (mm/dd/yyyy) <u>11/21/2007</u>	4. Date of this report (mm/dd/yyyy) <u>01/28/2009</u>

5. Describe event or problem
This is in follow-up to report(s) previously submitted on 6/2/2008; 6/4/2008; 8/12/2008; 1/26/2009

A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC)

Initial and follow-up information has been received from an investigator concerning a 61 year old white male with a target lesion into right adrenal gland, arterial hypertension, mediastinal lymph adenopathy and liver metastasis and a history of bronchoscopy who on 26-SEP-2007 was randomized to study, title as stated above. Concomitant therapy included dexamethasone, ondansetron, cimetidine and diphenhydramine HCl.

On 26-SEP-2007, the patient was placed on therapy with blinded therapy with either vorinostat, capsule, 400 mg, daily or placebo, administered orally on days 1-14 on

(Continued on Additional Page)

6. Relevant tests/laboratory data, including dates Refer to Additional Page
7. Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.) MEDICAL HISTORY: Bronchoscopy CONCURRENT CONDITIONS: Malignant neoplasm of adrenal gland; Hypertension arterial; Lymphadenopathy mediastinal; Metastases to liver

C. Suspect medication(s)	
1. Name (Give labeled strength & mfr/labeler)	
# 1 CAP 0683-blinded therapy 400 mg	
# 2	
(Continued on Additional Page)	
2. Dose, frequency & route used	3. Therapy dates (if unknown, give duration) from/to (or best estimate)
# 1 400 mg/DAILY/PO	# 1 09/26/2007 - 10/09/2007
# 2	# 2
4. Diagnosis for use (indication)	5. Event abated after use stopped or dose reduced.
# 1 Adenocarcinoma	yes no N/A unk
# 2	# 1 <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
6. Lot #	7. Exp. Date
# 1	# 1
# 2	# 2
9. NDC # or Unique ID	8. Event reappeared after reintroduction.
Unknown	yes no N/A unk
# 1	# 1 <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/>
# 2	# 2 <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
10. Concomitant medical products and therapy dates (excluded treatment of event)	
cimetidine	11/09/2007-11/09/2007
dexamethasone	11/08/2007-11/12/2007
(Continued on Additional Page)	

G. All manufacturers	
1. Contact office - name/address	2. Phone Number
Merck Human Health Division Merck & Co., Inc. P.O. Box 4 West Point, Pa. 19486-0004 Attn: World Wide Product Safety	(215) 652-8071
4. Date received by manufacturer (mm/dd/yyyy) <u>01/17/2009</u>	3. Report source. (check all that apply)
6. If IND, protocol # <u>0560042</u>	<input checked="" type="checkbox"/> foreign <input checked="" type="checkbox"/> study <input type="checkbox"/> literature <input type="checkbox"/> consumer health professional <input type="checkbox"/> user facility <input type="checkbox"/> company representative <input type="checkbox"/> distributor <input type="checkbox"/> other:
7. Type of report <input type="checkbox"/> 5-day <input type="checkbox"/> 30-day <input type="checkbox"/> 7-day <input type="checkbox"/> Periodic <input type="checkbox"/> 10-day <input type="checkbox"/> Initial <input checked="" type="checkbox"/> 15-day <input checked="" type="checkbox"/> Follow-up# <u>4</u>	5. (A)NDA # IND # <u>58915</u> STN # PMA/ 510(k) # Combination Product <input type="checkbox"/> Yes Pre-1938 <input type="checkbox"/> Yes OTC product <input type="checkbox"/> Yes
8. Adverse event term(s) HYPOTENSION	9. Mfr. report number WAES 0711USA07005

E. Initial reporter		
1. Name, address & phone #		
2. Health professional? <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	3. Occupation	4. Initial reporter also sent report to FDA. <input type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> unk

FDA

Submission of a report does not constitute an admission that medical personnel, user facility, distributor, manufacturer or product caused or contributed to the event.

B. Adverse event or product problem**5. Describe event or problem**

cycle 1 (cycle equivalent to 25 days) for the treatment of adenocarcinoma (diagnosed 22-AUG-2007; Stage IV, T2, N1, M1).

On 19-OCT-2007 the patient was administered a reduced dose of cycle 2 with either vorinostat, capsule, 300 mg, daily or placebo, carboplatin 850 mg, IV and paclitaxel 350 mg, IV.

On 09-NOV-2007 the patient was administered cycle 3 of with either vorinostat, capsule, 300 mg, daily or placebo, carboplatin 850 mg, IV and paclitaxel 375 mg, IV.

Concomitant study therapy included carboplatin, AUC equivalent to 6 (850 mg) and paclitaxel 200 mg/m² (400 mg) administered IV on day 1 of each treatment cycle.

On 16-NOV-2007 absolute neutrophil count was 4.01. Study medication was stopped by the patient independently on 20-NOV-2007. The patient's wife reported that on 21-NOV-2007, (cycle 3, day 13), the patient was hospitalized to the emergency care department with severe weakness, dizziness and low arterial pressure (80/40 mm Hg). The investigator indicated that the patient developed hypotension (grade 5) his condition was declining and therefore he was hospitalized. On 22-NOV-2007, (cycle 3, day 14) an active call to the patient was made as a reminder and necessity to come for delivery of analysis in the central laboratory. It was reported that the patient was not dehydrated and had not had any nausea, vomiting, diarrhea fever or infection. The patient did not receive any treatment specific to the hypotension. It was reported that the cardiac function was not assessed by the investigator because the patient was hospitalized to the emergency care department at another hospital. On 23-NOV-2007 the patient completed the study and discontinued study medication. On 24-NOV-2007, the patient died in the emergency care department by cardiovascular insufficiency. Pathomorphology diagnosis were listed as "cardiovascular and pulmonar insufficiency, NSCLC left lung with metastatic lung disease." It was also reported that the direct and dominant cause of death was cardiovascular and pulmonary insufficiency.

The reporting investigator considered hypotension, grade 5 to be immediately life-threatening.

The reporting investigator felt that hypotension, grade 5 was related to MK-0683 blinded study therapy but was not related to carboplatin or paclitaxel.

Additional information is not expected.

A 7 calendar day telephone/facsimilie report was made to the FDA on 02-JUN-2008.

6. Relevant tests/laboratory data, including dates**DIAGNOSTIC TEST**

<u>Tests</u>	<u>Date</u>	<u>Value</u> <u>Unit</u>	<u>Normal Range</u>
blood pressure measurement Comment: arterial pressure		80/40 mm Hg	

LABORATORY RESULTS

<u>Tests</u>	<u>Date</u>	<u>Value</u> <u>Unit</u>	<u>Normal Range</u>
absolute neutrophil count	11/16/2007	4.01	

C. Suspect medication(s)**1. Name (Give labeled strength & mfr/labeler)**

#1 CAP 0683-blinded therapy 300 mg
 #1 CAP 0683-blinded therapy 300 mg
 #2 infusion (form) carboplatin 850 mg
 #2 infusion (form) carboplatin 850 mg
 #2 infusion (form) carboplatin 850 mg
 #3 infusion (form) paclitaxel 400 mg
 #3 infusion (form) paclitaxel 350 mg
 #3 infusion (form) paclitaxel 375 mg

2. Dose, frequency & route used

#1 300 mg/DAILY/PO
 #1 300 mg/DAILY/PO
 #2 850 mg/1X/IV
 #2 850 mg/1X/IV
 #2 850 mg/1X/IV
 #3 400 mg/1X/IV
 #3 350 mg/1X/IV
 #3 375 mg/1X/IV

3. Therapy dates (if unknown, give duration) from/to (or best estimate)

#1 10/19/2007 - 11/01/2007
 #1 11/09/2007 - 11/20/2007
 #2 09/30/2007 - 09/30/2007
 #2 10/19/2007 - 10/19/2007
 #2 11/09/2007 - 11/09/2007
 #3 09/30/2007 - 09/30/2007
 #3 10/19/2007 - 10/19/2007
 #3 11/09/2007 - 11/09/2007

4. Diagnosis for use (indication)

#1 Adenocarcinoma
 #1 Adenocarcinoma
 #2 Adenocarcinoma
 #2 Adenocarcinoma
 #2 Adenocarcinoma
 #3 Adenocarcinoma
 #3 Adenocarcinoma
 #3 Adenocarcinoma

5. Event abated after use stopped or dose reduced

	YES	NO	N/A	UNK
#1		X		
#1		X		
#2			X	
#2			X	
#2			X	
#3			X	
#3			X	
#3			X	

6. Lot # (if known)

#1
 #1
 #2
 #2
 #2
 #3
 #3
 #3

7. Exp date (if known)

#1
 #1
 #2
 #2
 #2
 #3
 #3
 #3

8. Event reappeared after reintroduction

	YES	NO	N/A	UNK
#1			X	
#1			X	
#2			X	
#2			X	
#2			X	
#3			X	
#3			X	
#3			X	

• C. Suspect medication(s)

• 10. Concomitant medical products and therapy dates (exclude treatment of event)

diphenhydramine hydrochloride	11/09/2007 - 11/09/2007
ondansetron	11/09/2007 - 11/09/2007